Skip to main content
logo
Cell Biotech Co., Ltd. (KOSDAQ:049960)
South Korea flag South Korea · Delayed Price · Currency is KRW
15,840
+60 (0.38%)
At close: Sep 3, 2026

Cell Biotech Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
16,80010,12515,1276,3048,28110,383
Depreciation & Amortization
3,5983,6143,8723,9043,6383,789
Loss (Gain) From Sale of Assets
-438.96108.08-10.1482.450.91-29.05
Loss (Gain) From Sale of Investments
-267.83-868.86-575.56211.19--111.68
Provision & Write-off of Bad Debts
2.468.951.44-0.1-0.39-0.44
Other Operating Activities
-1,760-1,336167.48-215.9154.35441.37
Change in Accounts Receivable
402.2-140.62817.3151.0139.38144.48
Change in Inventory
-277.82-412.51-81.6-19.33-506.84-79.79
Change in Accounts Payable
-278.54-504.2138.76-875.3396.3271.08
Change in Unearned Revenue
6.145.70.54-3.86-19.548.92
Change in Income Taxes
24.24---643.39--
Change in Other Net Operating Assets
273.09509.17-90.03-979.121,13174.98
Operating Cash Flow
18,08311,10919,2677,81512,81414,892
Operating Cash Flow Growth
64.98%-42.34%146.53%-39.01%-13.96%55.71%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-7,255-3,105-1,129-1,552-2,368-848.59
Sale of Property, Plant & Equipment
-063.4879.501.716.77
Sale (Purchase) of Intangibles
4.442.14-113.83-123.92-304.225.86
Sale (Purchase) of Real Estate
-----14.92
Investment in Securities
12,1957,562-17,685-3,062-4,138-10,499
Other Investing Activities
45.2932.73213.0512.1738.622.6
Investing Cash Flow
5,0254,590-18,737-4,745-6,669-11,132

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Repaid
--612.73-661.5-641.07-636.49-676.15
Net Debt Issued (Repaid)
-617.68-612.73-661.5-641.07-636.49-676.15
Repurchase of Common Stock
-----3,719-
Dividends Paid
-4,106-3,080-3,080-3,080-3,182-3,182
Financing Cash Flow
-4,724-3,692-3,741-3,721-7,538-3,858

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
1,271375.5683.6576.91-9.33357.88
Miscellaneous Cash Flow Adjustments
00-0-0-
Net Cash Flow
19,65412,382-3,128-573.48-1,402260.35

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
10,8288,00418,1386,26410,44514,044
Free Cash Flow Growth
11.22%-55.87%189.57%-40.03%-25.62%116.55%
Free Cash Flow Margin
17.93%15.07%36.34%11.65%20.67%29.96%
Free Cash Flow Per Share
1581.351169.582649.95915.241515.031985.94
Levered Free Cash Flow
3,2153,7809,753-335.575,5479,207
Unlevered Free Cash Flow
3,2273,8009,791-296.855,5719,233

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
19.8832.5960.8861.9537.4942.48
Cash Income Tax Paid
1,7592,423-1,5391,3551,371-136.75
Change in Working Capital
149.31-542.47684.99-2,470740.73419.67